RBC Capital Reiterates Sector Perform on Darden Restaurants (DRI) Following 1Q Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Oppenheimer Reiterates Outperform on Darden Restaurants (DRI) Following 1Q Report
October 5, 2016 9:51 AM EDTOppenheimer reiterated an Outperform rating and $70.00 price target on Darden Restaurants (NYSE: DRI) following the company's 1Q earnings report. DRI reported EPS of $0.88, ahead of the Street's $0.82 estimate. Management raised F17E EPS guidance to $3.87-$3.97 (was $3.80-$3.90), vs. Street's $3.87.
Analyst Brian Bittner... More
Options with increasing volume: MTDR BRCD VNO
October 4, 2016 9:47 AM EDTOptions with increasing volume: MTDR BRCD VNO DRI BRCD NEM DAL NFLX HPE SDRL ETSY AAL NBR DOV BLDP TGP MUX
... MorePre-Open Stock Movers 10/04: (SMMT) (SDRL) (ARLZ) Higher; (TRIB) (IRMD) (TWTR) Lower (more...)
October 4, 2016 9:22 AM EDTToday's Pre-Open Stock Movers
Summit Therapeutics plc (Nasdaq: SMMT) 80% HIGHER; Sarepta Therapeutics (Nasdaq: SRPT) and Summit Therapeutics plc (Nasdaq: SMMT) announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States (the licensed territory), to Summits utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy (DMD). As part of the agreement, Sarepta also obtains an option... More
Darden Restaurants (DRI) Tops Q1 EPS by 6c; Boosts FY17 EPS Outlook; $500M Stock Buyback Approved
October 4, 2016 7:06 AM EDTDarden Restaurants (NYSE: DRI) reported Q1 EPS of $0.88, $0.06 better than the analyst estimate of $0.82. Revenue for the quarter came in at $1.71 billion versus the consensus estimate of $1.72 billion.
Same-restaurant sales increased 1.3% for the quarter.
Stock Buyback News:
During the... More
